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ABSTRACT
Factor VII (FVII) consists of an N-terminal gamma-carboxyglutamic acid domain followed by two epidermal growth factor-like (EGF1 and EGF2) domains and the C-terminal protease domain. Activation of FVII results in a two-chain FVIIa molecule consisting of a light chain (Gla-EGF1-EGF2 domains) and a heavy chain (protease domain) held together by a single disulfide bond. During coagulation, the complex of tissue factor (TF, a transmembrane glycoprotein) and FVIIa activates factor IX (FIX) and factor X (FX). FVIIa is structurally "zymogenlike" and when bound to TF, it is more "active enzymelike." FIX and FX share structural homology with FVII. Three structural biology aspects of FVIIa/TF are presented in this review. One, regions in soluble TF (sTF) that interact with FVIIa as well as mapping of Ca 2+ , Mg 2+ , Na + and Zn 2+ sites in FVIIa and their functions; two, modeled interactive regions of Gla and EGF1 domains of FXa and FIXa with FVIIa/sTF; and three, incompletely formed oxyanion hole in FVIIa/sTF and its induction by substrate/inhibitor. Finally, an overview of the recognition elements in TF pathway inhibitor is provided.
INTRODUCTION
Human factor VII (FVII) is a vitamin K-dependent trace plasma protein; it is synthesized by hepatocytes and secreted into blood as a single chain molecule of Mr ~50,000 (1, 2) . Starting at the N-terminus, FVII contains a gammacarboxyglutamic acid-rich domain (Gla domain, residues 1-38), a short hydrophobic segment (residues [39] [40] [41] [42] [43] [44] [45] that often is considered as part of the Gla domain, two epidermal growth factor (EGF)-like domains (residues 47-84 and 85-131) , and the C-terminal serine protease domain (residues 153-406) (3) . FVII has negligible activity and participates in the extrinsic pathway of coagulation principally after its activation to FVIIa (4-7). A number of coagulation enzymes including FXa, FIXa, and FVIIa can activate FVII (8-11); however, FXa appears to be the most potent activator of FVII (12) . Activation of FVII by each enzyme involves cleavage of a single peptide bond between Arg-c15{152} and Ilec16{153}, located in the connecting region between the EGF2 and the protease domain. This results in the formation of a two-chain FVIIa molecule consisting of a light chain of 152 amino acids and a heavy chain of 254 amino acids held together by a single disulfide bond (between Cys-135 and Cys-262) (3).
Tissue factor (TF) is a membrane protein with structural homology to the class 2 cytokine receptor family (13) . Human TF consists of an N-terminal cytoplasmic domain of 19 residues, a transmembrane domain of 23 residues and a C-terminal ectodomain domain of 219 residues. The ectodomain of TF consists of two fibronectin type-III repeats. The crystal structure of the C-terminal domain pair-soluble tissue factor (sTF)-is known (14) (15) (16) (17) ; the two fibronectin type-III domains are connected end-toend at an angle of 120 degrees (14) (15) (16) (17) . Similar to full-length TF, sTF binds FVIIa with high affinity and potentiates its enzymatic activity (18-20).
Binding of TF increases the amidolytic activity of FVIIa several-fold (21-23) by restructuring the active site region. In this regard, Higashi et al. (24) proposed that free FVIIa is structurally more zymogen-like and when bound to TF it is more active enzyme-like. Alanine scanning mutational studies of surface residues in the protease domain of FVIIa support this concept (25). Thus, TF binding induces the concerted structural rearrangements in FVIIa similar to those observed upon the proteolytic activation of trypsinogen to trypsin and related serine proteases (26). Further, these changes occur only when the free NH 2 -group of the Ile-c16{153} is allowed to make a salt bridge with the carboxylate of Asp-c194{343} of FVIIa (24). TF cannot induce these changes in zymogen FVII in which Arg152-Ile153 bond has not been cleaved (27). Although TF binding to FVIIa increases its activity by several orders of magnitude, it does not appear to do so by forming the oxyanion hole; it is the substrate that induces formation of the oxyanion hole in FVIIa (28). In the absence of TF, the FVIIa regions that play an important role in preventing the transition from the zymogen-like to the active enzyme-like molecule, and how TF binding promotes this transition is an area of active investigation (29-33), which is discussed elsewhere in this issue (34).
Initiation of coagulation begins by exposure of blood to TF in the extravascular space at an injury site and formation of the Ca 2+ -dependent complex between TF and plasma FVIIa. The Ca 2+ /FVIIa/TF complex formed on the cell surfaces then activates both FX and FIX leading to thrombin generation and fibrin formation. In this reaction, FVIIa, FX and FIX (see below) anchor to the phospholipid (PL) bilayer through their Gla domains for optimal rates of FXa and FIXa formation. Consequently, in the absence of PL, the rates of activation of FX and FIX by FVIIa/sTF are relatively slow (18) (19) (20) . TF pathway of coagulation is regulated by tissue factor pathway inhibitor (TFPI), a FXadependent inhibitor of the Ca 2+ /FVIIa/TF complex (35). The translated amino acid sequence of human TFPI (major form) cDNA reveals that it consists of a highly negative Nterminus, three tandemly repeated Kunitz-type domains with intervening linker regions, and a highly positive C-terminus (36). The mechanism of inhibition by TFPI involves its binding first to FXa through domain 2 and then to the TF/FVIIa complex through domain 1 (37, 38) . The third Kunitz-type domain has no inhibitory activity and has other biologic functions that will not be discussed here.
Human FX and FIX share structural homology with FVII. FX circulates as a zymogen with a molecular weight of ~59,000 and consists of a light chain (amino acids 1-139) and a heavy chain (amino acids 143-448) held together by a single disulfide bond between Cys-132 and Cys-c302 (3, 39) . Upon activation, a single peptide bond in FX between residues Arg-c15{194} and Ile-c16{195} is cleaved with resultant formation of a serine protease, FXa, and release of a 52-residue activation peptide (3). The NH 2 terminus light chain of human FXa contains 11 Gla residues and represents the Gla domain (residues 1-39); the Gla domain is followed by a few aromatic residues (amino acids [40] [41] [42] [43] [44] [45] , and two EGF-like domains (EGF1 residues 46-84, EGF2 residues 85-128). The heavy chain contains the serine protease domain essential for catalysis and features the active site triad of Hisc57{236}, Asp-c102{282}, and Ser-c195{379} (3).
FIX is a single chain protein and contains a Gla domain (residues 1-40), a short hydrophobic segment (residues [41] [42] [43] [44] [45] [46] , two EGF-like domains [residues 47-84 (EGF1) and 85-127 (EGF2)], an activation peptide region (residues 146-180), and a serine protease module (residues 181-415). Activation of FIX involves proteolytic cleavages at Arg145-Ala146 and Arg-c15{180} and Val-c16{181} bonds with a concomitant release of a 35-residue activation peptide (3, 40) . The FIXa thus formed contains a light chain (residues 1-145) and a heavy chain (residues 181-415) held together by a single disulfide bond. The light chain consists of the Gla, EGF1, and EGF2 domains whereas the heavy chain contains the serine protease domain that features the catalytic triad of residues Hisc57{221}, Asp-c102{269} and Ser-c195{365}.
In this review, we discuss the structural biology aspects of FVIIa/sTF interface and its interaction with the macromolecular substrates FIX and FX. The functional roles of Ca
2+
, Mg 2+ and Na + , and the inhibitory role of Zn 2+ in TF binding and catalysis are described. Unlike other serine proteases of the coagulation cascade, a unique feature of FVIIa bound to TF is the absence of oxyanion hole at the active site and its induction by the substrate. The importance of this mechanism in achieving selectivity of the physiologic substrate by FVIIa/TF is outlined. Lastly, an overview of the important recognition elements in the first and the second domain of TF pathway inhibitor (TFPI) is provided. Figure 1A and Figure 1B , respectively. In the 1DAN structure, the active site is occupied by D-Phe-PheArg-chloromethylketone and the oxyanion hole is fully formed. In the 2A2Q structure, the active site is occupied (41) 2+ in the 2A2Q structure. The Ca 2+ ion bound to the FVIIa EGF1 domain is labeled Ca8 and to the protease domain is labeled Ca9. In the 2A2Q structure Na + ion is labeled as Na and the two Zn 2+ ions labeled Zn1 and Zn2. The position of the active site Ser-195 is shown in ball and stick representation. The position of the C-terminal helix of the Gla domain (residues 34-45) of FVIIa is slightly tilted towards the TF2 domain in the 2A2Q structure resulting in a somewhat more favorable hydrophobic interactions between L13, F31 L39, and F40 of FVIIa with Y156, W158 and V207 of sTF. The residues interacting at the interface regions between FVIIa and sTF have been outlined in detail in an earlier report (41) .
MOLECULAR RECOGNITION IN TF-INDUCED COAGULATION
by p-aminobenzamidine (pAB) and the oxyanion hole is incompletely formed; the significance of this observation is discussed later in section 3.8. In both structures, FVIIa molecule is in an extended form where the protease domain is at the top and the membrane binding Gla domain is at the bottom. In this complex, FVIIa is tightly bound to sTF through salt bridges, hydrogen bonds, ionic contacts and hydrophobic interactions. All domains of FVIIa make strong interactions with sTF. These are outlined in detail earlier (41 
Modeled structures of FVIIa/sTF with FXa and with FIXa/FIX alpha
The FVIIa/TF complex activates FIX (63) as well as FX (64), which leads to the activation of prothrombin to thrombin. In a reciprocal fashion, FXa and FIXa activate FVII/TF (2, 8, 9, 12) . Although primary sequences of FXa and FIXa are highly homologous, the interaction of FIXa with FVIIa/TF is weaker than FXa (65, 66) ; further, as compared to FXa, FIXa is a poor activator of FVII/TF (12, 67) . Moreover, the affinities of FX-Gla and FX-EGF1 domains towards FVIIa/TF are stronger than the FIX-Gla and FIX-EGF1 domains (68) . To explain these differences, computational models of the ternary complexes of FVIIa/sTF-FXa, FVIIa/sTF-FIXa and FVIIa/sTF-FIX alpha have been proposed (67, (69) (70) (71) (72) . In building these models, biochemical evidence was combined with newly available algorithms for protein-protein docking (73) (74) (75) . In the absence of experimentally determined structures of FVIIa/sTF-FXa and FVIIa/sTF-FIXa or FVIIa/sTF-FIX alpha , these models serve as reasonable basis for understanding how Gla and EGF1 domains of FIX/IXa and FX/Xa interact with FVIIa/TF.
In 2003, structural models of the FVIIa/sTF-FXa complex were proposed by two independent groups, namely, the Scripps group (70) and the Chapel Hill group (71) . Based upon the methodology used to build these complexes, one is referred to as the Scripps static model (Ss model, 70) and the other as the original Chapel Hill solution-equilibrated model (CheA model, 71). Although different approaches were used, the two models have similar overall architecture and comparable residue interactions although with some significant variations. In general, each model was built in three stages using different protein-protein docking algorithms. In stage 1, the Protease-EGF2 domains of FXa were docked onto FVIIa/sTF. In stage 2 and stage 3, EGF1 domain and the Gla domain were docked onto FVIIa/sTF, respectively. At each stage the models were screened and those that corraborated the experimental evidence were selected for the next stage of modeling. The overall architecture of FVIIa/sTF-FXa is shown in Figure 2A . In both models, TF is sandwiched between the extended forms of FVIIa and FXa. Recently, both Ss and CheA model structures (70, 71) were subjected to 10 ns all-atom molecular dynamic simulations to obtain solution-equilibrated models (72) . The resulting models are referred to as Scripps solutionequilibrated (Se) and current Chapel Hill solutionequilibrated (CheB) models (72) . In all models, the Gla domain of FXa interacts with TF domain as well as with Gla domain of FVIIa. The EGF1 domain of FXa interacts only with TF in the Ss and Se models (70, 72) , whereas it interacts with TF and FVIIa in the CheA and CheB models (71, 72) . Further, in all models, the EGF2 domain and the serine protease (SP) domain of FXa interact with the serine protease domain of FVIIa and no interaction is noted with TF.
We used FVIIa/sTF-FXa as a template (1NL8, Ss model) to build the FVIIa-sTF-FIXa model (66) . Since the complete structure of FIXa is not available, we modeled the FIXa using the coordinates of FIXa Gla (58), EGF1 (76) (67) is based upon 1NL8 as the template. The FVIIa/sTF-FIX alpha model is from Chen et al (69) . As in figure 1 , FVIIa Gla, EGF1, EGF2, and the protease domains are colored red, green, blue and cyan, respectively. The sTF is shown in magenta. The Gla, EGF1, EGF2 and protease domains of FXa, FIXa and FIX alpha are colored deep teal, salmon, orange, and yellow, respectively. The active site residue (Ser-195) of FVIIa protease domain is shown in the space filling representation. The Ca 2+ ions bound to FVIIa are shown as orange spheres, whereas the Ca 2+ ions bound to FXa, FIX alpha and FIXa are shown as green spheres. Note that the Gla domains of FVIIa, FXa and FIXa are expected to bind Mg 2+ at specific sites under physiologic conditions. These sites have been replaced by Ca 2+ during model building.
and the protease-EGF2 domains (77) . The FIXa domains were structurally aligned to the respective domains of FXa in the FVIIa/sTF-FXa complex using the program 'O' (78) . To remove the steric clashes and the short contacts, the entire FVIIa/sTF-FIXa complex was subjected to minimization using CHARMM (79) . The resulting FVIIa/sTF-FIXa model is shown in Figure 2B . The model of FVIIa/sTF-FIX alpha complex (69) is shown in Figure 2C . Similar to FXa, the Gla domain of FIXa/IX alpha in FVIIa/sTF-FIXa or FVIIa/sTF-FIX alpha interacts with the Gla domain of FVIIa and TF, whereas the EGF1 domain interacts with TF only. However, the interactive residues in the FVIIa/sTF-FIXa and the FVIIa/sTF-FIX alpha models are different. Based on these computational models, we outline the possible mode of interactions between FVIIa/sTF and FXa/FIXa/FIX alpha in the next three sections.
Interactions of FVIIa/sTF with the Gla domains of FX/Xa and FIX/IXa
The C-terminal region of TF interacts with the Gla domains of FX/Xa (22, [80] [81] [82] [83] and FIX/IXa (66, 67, 69) . Further, the Gla domains of FX/Xa (68, (70) (71) (72) (73) and FIX/IXa (66,69) also interact with the Gla domain of FVIIa. The possible modes of interaction between FVIIa/sTF with the Gla domains of FXa (Ss model), FIXa and FX alpha are shown in Figure 3 A, B and C, respectively. Although the structures of FXa and FIXa are similar, the variations in their sequences at the interacting regions with sTF and with the Gla domain of FVIIa make associations different from each other. The residues 9 to 12 (KKGH) in the Gla domain of FXa are basic, whereas residues 10 to 13 in FIXa are hydrophobic and neutral (VQGN). The residues K10 and H12 in FXa make salt bridge with D33 of FVIIa. In comparison, Q11 in FIXa makes weak hydrogen bond with D33 of FVIIa. However, K38 of FVIIa makes a salt bridge with Gla14 in FXa and similarly with Gla15 in FIXa. Overall, the sequence variations in this region make interactions weak for FIXa.
The C-terminal helix of the Gla domains in FX/Xa and FIX/IXa interact with the C-terminal domain of TF and make no contact with FVIIa. In the Ss model, FXa residues Gla32, D35, and Gla39 make salt bridges with TF residues K166, R200, and K201, respectively ( Figure 3A ). In addition, K36 of FXa makes hydrogen bond with T167 of TF. The C-terminal helix of FIXa Gla domain interacts with TF in a similar fashion. In FIXa, corresponding residues Gla33, Gla36, and Gla40 make salt bridges with TF residues K166, R200, and K201, respectively. In addition, R37 of FIXa can make a hydrogen bond with either T167 or D204 of TF ( Figure 3B ). Mutagenesis studies support the role of TF residues R200, K201, T167 and K165 in its interaction with the Gla domain of FXa/FIXa (80) (81) (82) (83) . Thus, comparable interactions exist between the C-terminal helix of the Gla domains of FXa or FIXa with TF. A) The modeled interaction of FXa-Gla with sTF and FVIIa-Gla. FXaGla:sTF-Gla32:K166, D35:R200, Gla39:K201 and K36:T167; FXa-Gla:FVIIa-Gla-K10:D33, H12:D33 and Gla14:K38. B) The modeled interaction of FIXa-Gla with sTF and FVIIa-Gla. FIXa-Gla:sTF-Gla33:K166, Gla36:R200, R37:D204/T167, and Gla40:R200/K201; FIXa-Gla:VIIa-Gla-Q11:D33 and Gla15:K38. C) The modeled interaction of FIX alpha -Gla with sTF and FVIIa-Gla. FIX alpha -Gla:sTF-Gla15:N184, C23:S162, Q44:D180/201 and Y45:S163; FIX alpha -Gla:FVIIa-Gla-Gla7:K32; M19:R36, Gla20:F31/I30 and Gla21:R28/K32. Interactions of the Gla domain of FXa with TF and FVIIa in the CheA/CheB models (71, 72) are somewhat different from the Ss/Se models (70, 72) . The important differences are-a) ionic interactions between K165 of TF and D35 of FXa present in the CheA/CheB models and absent in the Ss/Se models; and b) ionic interactions between R36 of FVIIa and Gla14 of FXa present in the Ss/Se models and absent in the CheA/CheB models. By mutagenesis, residue R36 in Gla domain of FVIIa has also been identified as one of the key residues in substrate recognition of FX (84) . However, our recent FVIIa/sTF crystal structure at 1.72 angstrom reveals that R36 in FVIIa is involved in network of hydrogen bonds with TF (56). Further in this structure, the TF region containing residues K165 and K166 are well defined and it appears that only one of these residues side chain can interact with FXa. Moreover, hydrophobic interactions between the Gla domains of FVIIa and FXa are more prominent in the CheA/CheB models as compared to the Ss/Se models. Clearly, experimentally determined structure of FVIIa/sTFFXa is needed to resolve these discrepancies.
As compared to FIXa, the mode of interaction between the Gla domain of FIX alpha and the FVIIa/sTF is considerably different. The FIX alpha Gla residues that interact with FVIIa/sTF are shown in Figure 3C . These interactions involve possible hydrogen bonds between residues Gla7, Gla15, M19, Gla20, and Gla21 of FIX alpha with R28, I30, F31, K32, and R36 of FVIIa and N184 and S162 of TF. The Gla domain C-terminal helix residues Q44 and Y45 of FIX alpha also interact with residues S163, D180 and K201 of TF via hydrogen bonds. In general, FIX alpha versus FIXa Gla domain interacts strongly with FVIIa/sTF. Again, experimentally determined structures are needed to resolve these anomalies.
Interactions of FVIIa/sTF with the EGF1 domains of FX/Xa and FIX/IXa
The experimental evidence indicates that EGF1 domain participates in the complex formation of FVIIa/sTF with FIX (66, 85) and FX (66, 70, 86) , and in the reciprocal activation of FVII/TF (67) . In FIX/FIXa, side chains of residues E52, N54 and N58 interact with complimentary side chains of K15/N107, N199/E105 and E99 in sTF, respectively (Figure 4) . Similarly in the Ss model, side chains of residues E51, S53 and N57 in FX/Xa interact with side chains of K15, E105 and E99 in sTF, respectively. In addition, side chains of T52, Q58 and K60 in FX/Xa interact with side chains of T13, T101 and T197 in sTF, respectively. Carbonyl oxygen of C50 in FXa may also interact with N199 side chain nitrogen of sTF ( Figure  4) . Thus, based on the Ss model, sTF interacts stronger with EGF1 domain of FX/Xa than of FIX/IXa.
The mode of interactions of EGF1 domain of FX/Xa in the CheA/CheB models is distinct from the Ss/Se models. In the CheA/CheB models, the E51 of FXa interacts with K201 of sTF (72) ; the residue E51 of FXa interacts with K15/N107 of sTF in the Ss model. None of the other residues of FXa proposed in the Ss/Se models interact with sTF in the CheA/CheB models. In the CheB In the FVIIa/sTF-FIX alpha model, the mode of interaction is different from the FVIIa/sTF-FIXa model. The N54 in FIX alpha interacts with K169 of sTF, whereas N54 in FIXa interacts with N199 of sTF. As compared to FIXa, all other residues in FIX alpha that are proposed to interact with sTF are different ( Figures 4B and 4C) . In FIX alpha , D49, D64, and K63 interact with K165, K166 and Y157 of sTF, respectively.
Interactions of FVIIa-protease domain with the protease domains of FXa, FIXa and FIX alpha
The possible mode of interactions between FVIIa protease domain with the protease domains of FXa, FIXa and FIX alpha are shown in Figure 5 A, B and C, respectively. In FVIIa/sTF-FXa Ss model (Figure 5A ), the side chains of Q-c20{200}, K-c23{203}, K-c134{318}, Kc186{371}, R-c202{387}, K-c204{389} and D-c205{390} from FXa interact with main and or side chains of Lc153{295}, T-c151{293}, D-c186{334}, E-c154{296}, Sc188A{336}, D-c186{334} and D-c146{289}/Rc147{290} from FVIIa, respectively. In addition, main chain oxygen of V-c160{343} from FXa interact with side chain nitrogen of K-c20{157} from FVIIa. Notably, Rc147{290} in FVIIa is also implicated to be important in FX activation (87) .
Predicted interactions of FVIIa-protease domain with FXa in the Se model are shown in Table 1 (72) . Comparative interactions in the CheB are also shown in table 1 (72) . Clearly, there are differences between the Se and CheB models. Moreover, only three interactions involving K20, D186, and S188A of FVIIa protease domain and V160, K134 and R202 of FXa protease domain are common between the Ss and the Se model.
In FVIIa/sTF-FIXa complex, G-c19{184}, Kc23{188}, R-c159{327}, V-c160{328} and E-c204{374} from FIXa make hydrogen bonds with E-c154{296}, Tc151{293}, G-c19{156}, K-c20{157} and Dc186{334}/A-c221A{369} from FVIIa, respectively. In the FVIIa/sTF-FIX alpha model, the exosite residues Qc26{191}, R-c159{327}, E-c186{355} and Rc188A{358} from FIX alpha interact with R-c147{290}, G-c19{156}, R-c147{290} and D-c72{212}/Ec154{296} of FVIIa. There are obvious differences between the FIXa and FIX alpha interactions with FVIIa. In addition to the inherent accuracies of the models, the apparent differences also stem from the fact that FIXa is in the enzyme form and the FIX alpha is in the zymogen form.
From the foregoing, it is clear that there are limitations to the accuracy and reliability of the modeled complexes. Despite these limitations, they provide useful information to design mutagenesis experiments. Experimentally determined structures are needed to precisely define the interactive regions in the ternary complexes. In fact, how protease domains of zymogen FX and FIX interact with FVIIa/sTF should be the primary defining interactions between the FVIIa/sTF and FX/FIX. Further, we know from the K M data (65, 66) that FX and FIX interact to FVIIa/TF with equal affinity whereas FXa and FIXa interact differently. Knowing how zymogens FX and FIX interact with FVIIa/TF will answer these lingering questions. One also needs to know, how FXa and FIXa interact with FVII/TF in the reciprocal activation.
Interface between EGF2/Protease domains of FVIIa with sTF
The protease domain of FVIIa has a fold similar to that of other serine proteases. It consists of two betabarrel structures with three alpha-helical segments. Based upon the experimentally determined structures (PDB id 1DAN and 2A2Q), the interface between the EGF2 and the protease domains of FVIIa and sTF is shown in Figure 6 . Residues from all three alpha-helices of FVIIa protease domain make hydrogen bond with N-terminal domain of TF. These involve residues F-c129F{276}, R-c134{277}, T-c165{307}, Q-c166{308}, D-c167{309}, and Rc230{379} of FVIIa with S39, D44, W45, E91, Y94 and N96 of TF. In addition K85 of EGF2 domain makes hydrogen bond with D61 of TF.
The loop residues on the either side of the c130 and c160 helical segments of FVIIa interact with TF as well as with the EGF2 domain of FVIIa. The key residues identified to be important in increasing the activity of FVIIa were found in this interface region. The side chain of residue M-c164{306} implicated in allosteric activation of FVIIa is snuggly fitted into the hydrophobic pocket comprised of F76, P92 and Y94 of sTF (28,41). This hydrophobic pocket is lined by sTF residues R74 and N96. Substitution of M-c164{306} by Asp essentially abolishes the TF induced allosteric activation of FVIIa (88) . This may be, in part, due to interaction of Asp-c164{306} of FVIIa with side chain of N96 of sTF (88); alternatively Asp-c164{306} could make hydrogen bond with R74. In either case, this could alter the c160 loop in FVIIa and impair its allosteric activation. Moreover, substitution of R74 by Ala in sTF (89) could affect the F76/P92/Y94 hydrophobic pocket and disallow the proper fixation of Mc164{306} in FVIIa. Thus, R74A mutant of sTF appears to have an indirect effect on FVIIa allosteric activation rather than playing a direct role.
The EGF2 domain strongly interacts with the FVIIa-protease domain through the hydrogen bonds and hydrophobic interactions. The residues involved in hydrogen bond formation are shown in Figure 6 . EGF2 domain residues C102, D104, N95, Y101, R113, H115, and G136 interact with T-c129C{272}, R-c129B{271}, Ec125{265}, P-c120{260}, and L-c123{263} in the protease domain. In addition, the EGF2 domain stabilizes the FVIIa protease domain by shielding the hydrophobic residues on the surface of the protease domain. In the absence of such contacts, the shielded hydrophobic surface of the protease domain will be exposed to the solvent, which could lead to destabilization of the protease domain. Hence, these two domains are considered to represent a single structural unit.
Na + -site and Zn 2+ -sites in the protease domain of FVIIa and their functional roles
In the FVIIa/sTF complex, Na + ion was located in the region involving c184{332}-c191{340} and c220{368}-c225{374} loops; this region is homologous to the proposed site in FIXa, FXa and APC but not to thrombin (28). Na + is coordinated to the backbone carbonyl oxygens of Tyr-c184{332}, Ser-c185{333}, Hisc224{373}, Thr-c221{370} and two water molecules ( Figure 7A ). Further, one of the water molecules is hydrogen bonded to Asp-c189{338}. Since there is a three residue insertion in the c183 loop of thrombin (90) , Na + site in thrombin is coordinated to the carbonyl groups of c221 and c224, and four water molecules (91) . Binding of Na + to FVIIa modestly increases its affinity for TF (28). This is consistent with the observations that the Na + -site in FXa and FIXa increases the affinity for FVa and FVIIIa, respectively (92, 93) . Further, similar to FXa binding to FVa (92) and FIXa binding to FVIIIa (93) , binding of FVIIa to TF diminishes the effect of Na + on its activity (94, 95) . Notably, zymogen forms of thrombin, FXa, FIXa, and FVIIa each lack Na + -site and is developed during conversion to their respective enzymatic form. Thus, Na + binding to these enzymes contributes to their structural stability.
Two putative Zn 2+ sites have been identified in the protease domain of FVIIa (28, 96) . In an earlier report, Zn 2+ increased the binding of FVIIa to TF expressed on the bladder carcinoma J82 cells (97) . However, in subsequent direct binding studies, it was found that Zn 2+ reduces the affinity of FVIIa for sTF (96) . Importantly, Zn 2+ inhibits the proteolytic activity of FVIIa more potently than FVIIa/TF (96, 97) . Mutagenesis experiments and modeling studies predicted that the residue His-c76{216} and Hisc117{257} are involved in Zn 2+ binding to the protease domain of FVIIa (96) . The residues His-c76{216}, Gluc80{220}, Ser-c82{222} and three water molecules provide ligands for the first Zn 2+ -site and residues His-c117{257}, Lys-c24{161}, Asp-c79{219}, Gly-c69{209} and two water molecules provides ligand for the second Zn , whereas Zn2 and Ca 2+ are interconnected through a network of hydrogen bonds involving two water molecules ( Figure 7B ). Overlapping Ca 2+ and Zn 2+ -sites, in part, could provide explanation for experimental observations that the inhibitory effect of Zn 2+ is substantially reversed by Ca 2+ (96) . In this regard, inhibition by Zn 2+ is partially overcome by the allosteric activation and stabilization of the FVIIa protease domain induced by binding of TF to residues c164{306}-c167{309} and Ca 2+ binding to residues E-c70{210}-E80{220} (96).
Incompletely formed oxyanion hole in FVIIa/sTF and its induction by substrate/inhibitor
A defining feature of each serine protease, including those contained divergent folds from the chymotrypsin/trypsin, subtilisin, and the carboxypeptidase families, is the presence of an oxyanion-binding site, universally known as the oxyanion hole (98) . In the chymotrypsin/trypsin like proteases, Gly-c193 and Serc195 backbone amide nitrogens form this binding site. The neculeophilic attack by the hydroxyl group of Ser-c195 on the carbonyl carbon atom of the substrate changes the geometry around this carbon from trigonal planar to tetrahedral. This tetrahedral transition state intermediate is intrinsically unstable because of the negative charge on the A) The modeled interaction between FXa protease domain and FVIIa protease domain. FXa-protease:FVIIa-protease-Q20:L153/E154; K23:T151; K134:D186; V160:K20; K186:E154; R202:S188A; K204:D186; and D205:D146/R147. B) The modeled interaction between FIXa protease domain and FVIIa protease domain. FIXa-protease:FVIIa-protease-G19:E154; K23:T151; R159:G19; V160:K20 and E204:D186/A221A. C) The modeled interaction between FIX alpha protease domain and FVIIa protease domain. FIX alpha -protease:FVIIa-protease-Q26:R147; R159:G19; E186:K24; R188A:D72/E154. The P1 residue R15 in FIX alpha is shown to interact with D189 and S190 of FVIIa. The typical hydrogen bond observed between the main chain nitrogen of P1 residue (R15 in FIX alpha ) and the main chain oxygen of residue S214 in FVIIa is also shown. The chymotrypsin numbering scheme is used to label the residues. The insertion residues are labeled with the number followed by an alphabet A, B, etc. Figure 6 . FVIIa-protease, FVIIa-EGF2 and sTF interface interactions. Interactive residues at the interface region of FVIIa protease domain (cyan), EGF2 domain (salmon) and sTF (magenta and yellow) are shown in stick representation. For clarity, either the side chain or main chain atoms that are involved in hydrogen bonding interactions are shown. The hydrogen bonds are represented by black dashed lines. Blue and red represent nitrogen and oxygen atoms, respectively. The residues N95, Y101, C102, D104, R113, H115 and G136 from EGF2 domain interact with P120, L123, E125, R129B and T129C of the protease domain. The residues S39, D44, W45, E91, Y94 and N96 of sTF interact with R134, T165, D167, Q166 and R230 of FVIIaprotease domain. The residue K85 of FVIIa-EGF2 domain makes hydrogen bond with D61 of sTF. Between the FVIIa-EGF2 and sTF, the hydrophobic interactions are more dominant (not shown). The chymotrypsin numbering scheme is used to label the residues.
peptide carbonyl oxygen atom. However, in serine proteases this charge in the oxyanion hole is stabilized by H-bonds with the amide NH groups of Ser-c195 and Glyc193 in a site usually referred to as the oxyanion hole. These interactions result in preferential binding of the substrate in the transition state, a necessary requirement for enzyme catalysis.
Although the presence of an oxyanion hole is an essential feature of serine proteases and its geometry is not disrupted by inclusion of benzamidine or pAB at the bottom of S1 site (26, 98, 99) , it is absent in pAB-FVIIa/sTF (PDB id 2A2Q) or the benzamidine-FVIIa/sTF(PDB id 2AER) structures (28). This is shown in Figure 8A . The absence of an oxyanion hole in FVIIa/sTF was initially observed with an amidinophenylurea-based inhibitor (100). However, this was attributed to the unusual nature of the inhibitor, in which the amidino NH groups of the inhibitor induced ~180 degree rotation of the c192-c193 peptide bond such that the interactions between the NH groups of the inhibitor could occur with the c192 main chain C=O group (100), Thus, a normal conformation of the c192-c193 peptide bond would be changed to the unexpected nonstandard one. Flipped peptide bond between Lys-c192 and Gly-c193 of FVIIa has also been observed by Olivero et al. (101) and by Zbinden et al. (102) . In these structures, nitrogen at the para position of benzamidine moiety of the sulfonamide inhibitor (101) or the phenylglycine amide inhibitor (102) makes hydrogen bond with the main chain carbonyl group of Gly-c192 and the hydroxyl group of Serc195. Based upon the benzamidine-VIIa/sTF (PDB id 2AER) and the pAB-FVIIa/sTF (PDB id 2A2Q) crystal structures, one can safely conclude that the abnormal conformation of the c192-c193 peptide bond in FVIIa/sTF Note that there is a 180° flip in the peptide bond between K192 and G193 residues as compared to the structure with pAB shown in 'A'. Now, the carbonyl oxygen of K192 makes hydrogen bond with the backbone amide nitrogen of Q143, and the O delta of Q143 makes hydrogen bond with R147 (not shown). C) The fully formed oxyanion hole in free FVIIa with benzamidine and sulfate ion in the active site (PDB id 1KLI). The negatively charged sulfate ion in the active site is hydrogen bonded to the amide nitrogen of G193; this interaction induces the formation of oxyanion hole in this structure. D) The K192-G193 peptide bond in standard conformation after removal of the sulfate ion from the FVIIa active site (PDB id 1KLJ). The crystals were obtained under the same condition as that in panel 'C'; however benzamidine and the sulfate ions were removed by washing the crystal in the buffer lacking benzamidine and sulfate.
is not related to the presence of the unusual inhibitors in the active site; instead it is an inherent property of the FVIIa active site.
Importantly, TF does not increase the activity of FVIIa by inducing the formation of the competent oxyanion hole. It is the occupancy by an oxyanion of the substrate (or substrate analogue) at the active site that provides energy for 180 degree flipping of the c192-c193 peptide bond in FVIIa/sTF crystals. Thus, when the benzamidine-VIIa/sTF crystals were soaked with either EGRck (PDB id 2B8O) or with D-FPRck (PDB id 2FIR), the benzamidine was displaced by the EGR or the DFPR; consequently, the standard conformation of the c192-c193 peptide bond was observed. The D-FPR-FVIIa/sTF active site configuration is shown in Figure 8B . Furthermore, in the benzamidineFVIIa/sTF crystals the 192-193 conformation is stabilized by the hydrogen bond between Gly-c193 N and the side chain of Gln-c143. In contrast, in the EGR-FVIIa/sTF, D-FPRFVIIa/sTF, D-FFR-FVIIa/sTF, and the BPTI mutant-FVIIa/sTF (103) crystals, the c192-c193 conformation is stabilized by the hydrogen bond between main chain oxygen of c192 and the main chain N of Q-c143.
The structures (PDB id 1KLI and 1KLJ) of the EGF2/protease domain of FVIIa (104) obtained in the absence of TF support the concept that substrate/inhibitor transition state analog can induce the formation of oxyanion hole in FVIIa. In this structure, the bottom of the S1 site is occupied by benzamidine and top of the S1 site is occupied by a sulfate ion (104) . Here, the sulfate anion occupies the position normally occupied by the oxyanion of the carbonyl group of the P1 substrate/inhibitor residue in the transition state. This is shown in Figure 8C . Similar to the negatively charged oxygen in the tetrahedral transition state intermediate during catalysis, oxygen of the sulfate ion in this structure makes a hydrogen bond with amide nitrogen of Gly-c193. Thus, it is quite conceivable that occupancy of sulfate ion in the S1 site of FVIIa induced 180° flip of the c192-c193 peptide bond during crystallization. Moreover, as in the structures of EGRFVIIa/sTF, D-FPR-FVIIa/sTF, D-FFR-FVIIa/sTF, and mutant BPTI-FVIIa/sTF, carbonyl oxygen of Lys-c192 in the 1KLI structure makes hydrogen bond with the main chain nitrogen of Gln-c143. Upon removal of the sulfate ion by washing the crystal under sulfate free condition, the standard conformation of the oxyanion hole was maintained ( Figure 8D ). This could be due to stabilization by the hydrogen bond between carbonyl oxygen of c192 and the main chain nitrogen of c143. These observations lend support to a concept that the oxyanion hole in FVIIa is induced by the substrate/inhibitor and not by TF.
The Gla and EGF1 domains of FIX and FX represent the primary recognition determinants in binding to the FVIIa/TF and formation of the ternary complex (66, 67, (69) (70) (71) (81) (82) (83) (84) (85) (86) 105) . In the formed ternary complex, the scissile peptide bond sequence in FIX or FX then approaches the active site cleft in FVIIa and induces the formation of the oxyanion hole for efficient proteolysis. This exosite recognition mechanism between the enzyme and the substrate provides unique selectivity in activation of FIX and FX by FVIIa/TF under physiologic conditions in the presence of other plasma proteins.
Interactions of FVIIa with Kunitz domain-1 of TFPI and of FXa with Kunitz domain-2 of TFPI
TF induced coagulation is primarily regulated by TFPI. The N-terminal Kunitz domain-1 of TFPI inhibits FVIIa and the Kunitz domain-2 inhibits FXa. The residues of FVIIa that interact with Kunitz domain-1, and of FXa that interact with Kunitz domain-2 have been detailed earlier (35, 103, 106) . Among others, Kunitz domain-1 residues that are important for interaction with FVIIa appear to be D11, R20, and E46. Residue D11 interacts with R147 and K192 of FVIIa; R20 interacts with D60 of FVIIa, and E46 interacts with K60A/K60C of FVIIa. Similarly, among other residues, Kunitz domain-2 residues that are important for interaction with FXa appear to be Y17, R32, and E46. Residue Y17 fits into a hydrophobic cavity with possible interactions with R143 and Q151 of FXa; R32 interacts with E39 of FXa, and E46 interacts with K62 of FXa. The TF residues that interact with FXa in the FVIIa/sTF-FXa ternary complex appear to be also involved in the FVIIa/sTF-FXa-TFPI quaternary complex (107) . The precise interactions between the Kunitz domain-1 and FVIIa protease domain and between the Kunitz domain-2 and FXa protease domain must await until the experimentally determined structures are available.
PERSPECTIVE AND FUTURE DIRECTIONS
At the time of writing this review, we know the experimentally determined structures of only FVIIa with or without sTF. Further all structures are with active site inhibited FVIIa. Thus how FVIIa become more active when bound to sTF remains difficult to define precisely. To obtain insight in to this observable fact, structures of the protease domain of FVIIa plus/minus sTF without occupancy of the active site with an inhibitor are needed. Experimentally determined structure of the zymogen form of FVII also remains to be determined. These are daunting tasks and challenges that need to be undertaken. Further, sodium site and the zinc sites in FVIIa need to be confirmed by anomalous data collection. Crystals of ternary complexes of FVIIa with FIX and FX are to be obtained in order to understand the differences in affinity of VIIa/TF for FIX/IXa and FX/Xa and their interactive sites. Again, this may be a difficult task since FVIIa will cleave FIX and FX when zymogens are used. One way is to use Serc195Ala mutant of FVIIa for such studies. Recently, in addition to calcium, magnesium has been implicated in promoting the TF-induced coagulation that has not been addressed structurally. Finally, to understand the molecular regulation in TF-induced coagulation, one needs to obtain crystals of FVIIa/FXa/TFPI/sTF complex and solve its structure.
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